Exhibit 10.4

BIOSIG TECHNOLOGIES, INC.
12424 Wilshire Blvd, Suite 745
Los Angeles, CA 90025
February 14, 2018
Investors listed on signature page hereto

Re: Consent
Ladies and Gentlemen:
Reference is made to that certain Securities Purchase Agreement, dated as of
November 3, 2017 (the “Securities Purchase Agreement”), by and among BioSig
Technologies, Inc., a Delaware corporation (the “Company”), and certain
purchasers identified on the signature pages thereto, including the investors
listed on the signature page hereto (the “Investors”), as amended to date, and
that certain Certificate of Designation of Preferences, Rights and Limitations
of Series D Convertible Preferred Stock of the Company, dated November 3, 2017
(the “Certificate”), as amended to date.  All capitalized terms in this letter
(the “Letter Agreement”) shall have the meanings assigned to them under the
Securities Purchase Agreement, unless otherwise defined herein.
The Company is contemplating entering into a transaction pursuant to the terms
set forth in the forms of Securities Purchase Agreement (the “Series E Purchase
Agreement”), Certificate of Designation of Preferences, Rights and Limitations
of Series E Preferred Stock (the “Series E Certificate”) of the Company and
Warrant to Purchase Common Stock in the forms attached hereto as Exhibit A, 
Exhibit B and Exhibit C, respectively (the “Series E Financing”).  By signature
and countersignature below, the Company and the Investors agree to the
following:
1)
The Investors expressly consent to the Series E Financing in all respects,
including, without limitation, the Company’s issuance of securities pursuant to
the Series E Purchase Agreement and filing of the Series E Certificate with the
Secretary of State of the State of Delaware.

2)
From the date of the closing of the Series E Financing and expiring on the 60th
day following such date, each Investor may elect, in its sole discretion, to
exchange all or some of the Company’s Series D Convertible Preferred Stock held
by such Investor for any securities issued to purchasers in the Series E
Financing on a $1.00 per stated value for $1.00 new subscription amount basis
or, at the option of such Investor, amend the Transaction Documents to give each
Investor any or all of the more favorable terms of the Series E Financing. The
surrender of Series D Convertible Preferred Stock shall be in lieu of any cash
subscription amount required for the participation in the Series E Financing. By
way of example, if an Investor elects to subscribe for $100,000, then the
Investor shall have the right to surrender the $100,000 in stated value of
Series D Convertible Preferred Stock in lieu of cash consideration in the Series
E Financing of $100,000.

3)
The consent of the Investors set forth in this Letter Agreement shall be limited
as written in the manner and to the extent described herein and nothing in this
Letter Agreement shall be deemed to constitute a waiver of compliance by the
Company with respect to any other term, provision or condition of the Securities
Purchase Agreement or the Certificate, or any other instrument or agreement
referred to therein. To the extent of a conflict between the terms of this
Letter Agreement and the Securities Purchase Agreement, the terms of this Letter
Agreement shall control. The Securities Purchase Agreement and this Letter
Agreement shall be read and construed as one agreement.

--------------------------------------------------------------------------------

In consideration of the foregoing, each Investor shall receive a common stock
purchase warrant in the form attached hereto as Exhibit D to purchase such
amount of the Company’s common stock as set forth across from each Investor’s
name on Schedule I hereto.
[Signature Page Follows]
 
 
 

--------------------------------------------------------------------------------

[Signature Page to Side Letter]
Very truly yours,

BioSig Technologies, Inc.

By:                                                                    
Name:  Kenneth L. Londoner
Title:  Chief Executive Officer
 
 

--------------------------------------------------------------------------------

 
Acknowledged and Agreed:

   
Name of Investor:
Names of Investors (if held jointly, as tenants in common, or as community
property):
        By:______________________________ By: __________________________
Name:   
Title:   
Name:
Title:

                                                                                                                                                                     
        

  By: __________________________  
        Name:
 
         Title:

 

 

--------------------------------------------------------------------------------

EXHIBIT A

[Series E Purchase Agreement]
 
 
 
 

--------------------------------------------------------------------------------

EXHIBIT B

[Certificate of Designation of Preferences, Rights and Limitations
Of Series E Convertible Preferred Stock]
 
 

--------------------------------------------------------------------------------

EXHIBIT C

[Form of Warrant to Purchase Common Stock]
 
 
 

--------------------------------------------------------------------------------

EXHIBIT D
[Form of Investor’s Common Stock Purchase Warrant]
 
 
 

--------------------------------------------------------------------------------

Schedule I

Investor
 
Number of Warrant Shares